PDF
ePub
Citation
Print
Abstract
Stenotrophomonas maltophilia is a motile, non-fermentative, gram-negative rod. It is one of the important nosocomial pathogens associated with substantial morbidity and mortality such as pneumonia and bacteremia in immunocompromised patients. It should be carefully examined in the course of identification because it is frequently isolated together with other non-fermentative, gram-negative rods from clin-ical specimens. We report an isolate of S. maltophilia showing an oxidase-positive reaction, which is very rare for the species.
References
1. Lipuma JJ, Currie BJ, Lum GD, Vandamme PAR. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevun-dimonas, Comamonas, Delftia, and Acidovorax. Murray PR, Baron EJ, editors. Manual of Clinical Microbiology. 9th ed. .,. Washington: American Society for Microbiology;2006. p. 749–69.
2. Chong Y, Lee K, Kim HS, Lee SY. Diagnostic Microbiology. 3rd ed.Seoul: Seoheung Publishing Company;2000. p. 235–52.
3. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001; 32:S104–13.
4. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child. 1992; 67:192–5.
5. Wu PS, Lu CY, Chang LY, Hsueh PR, Lee PI, Chen JM, et al. Stenotrophomonas maltophilia bacteremia in pediatric patientsa 10-year analysis. J Microbiol Immunol Infect. 2006; 39:144–9.
6. The Johns Hopkins Medical Institutions. Stenotrophomonas. The Johns Hopkins Microbiology Newsletter.http://pathology5.pathology.jhmi.edu/micro/v17n14.htm. [online].
7. Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990; 11:134–8.
8. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect. 1995; 30:S453–64.
9. Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer. 2007; 109:2615–22.
10. Caylan R, Yilmaz G, Sucu N, Bayraktar O, Aydin K, Kaklikkaya N, et al. Nosocomial Stenotrophomonas maltophilia infections in a university hospital. Mikrobiyol Bul. 2005; 39:25–33.
11. Nseir S, Di Pompeo C, Diarra M, Brisson H, Tissier S, Boulo M, et al. Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study. Crit Care Med. 2007; 35:1318–23.
12. Burdge DR, Noble MA, Campbell ME, Krell VL, Speert DP. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis. 1995; 20:445–8.
13. Sattler CA, Mason EO Jr, Kaplan SL. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis. 2000; 31:1321–30.
Table 1.
Biochemical characteristics of Stenotrophomonas maltophilia isolate from the patient
XML Download